Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
25 Septiembre 2023 - 6:00AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical stage
genetic medicines company focused on developing transformative
therapies for central nervous system (CNS) disorders, today
announced that William Chou, M.D., president and chief executive
officer, will participate in a fireside chat at Chardan’s 7th
Annual Genetic Medicines Conference on Monday, October 2, 2023 at
5:00 p.m ET.
A live webcast of the event will be available on the Investors
& Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentation will be
available for 30 days following the event.
About Passage Bio Passage Bio (Nasdaq: PASG) is
a clinical stage genetic medicines company on a mission to provide
life-transforming therapies for patients with CNS diseases with
limited or no approved treatment options. Our portfolio spans
pediatric and adult CNS indications, and we are currently advancing
clinical programs in GM1 gangliosidosis and frontotemporal dementia
and our preclinical pipeline, including programs in amyotrophic
lateral sclerosis and Huntington’s disease. Based in Philadelphia,
PA, our company has established a strategic collaboration and
licensing agreement with the renowned University of Pennsylvania’s
Gene Therapy Program to conduct our discovery and IND-enabling
preclinical work. Through this collaboration, we have enhanced
access to a broad portfolio of gene therapy candidates and future
gene therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies. As we work
with speed and tenacity, we are always mindful of patients who may
be able to benefit from our therapies. More information is
available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Passage Bio (NASDAQ:PASG)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024